Targeting the osteoporotic bone microenvironment: Mechanistic insight and therapeutic biomaterials for accelerating bone regeneration
Source abstract
Abstract
Osteoporotic bone defects (OBD) present a major clinical challenge, largely due to a pathological bone microenvironment that severely compromises regenerative capacity. Moving beyond conventional classification schemes that often fail to capture this pathological complexity, our review establishes a conceptual framework that categorizes emerging biomaterials by mirroring the intrinsic functional components of the bone microenvironment itself—namely, ion-releasing, metabolite-based, extracellular matrix (ECM)-mimetic, and cytokine-loaded systems. The component-centric taxonomy not only systematizes a disparate field but also directly links material design to underlying pathological mechanisms. Accordingly, these materials are engineered not merely as structural replacements but as active modulators designed to reprogram the pathological niche by concurrently targeting key mechanisms such as cellular dysfunction and immune-metabolic dysregulation. Furthermore, we explore the emerging roles of bone organoids and artificial intelligence (AI) in refining preclinical models. By integrating a deep biological understanding of the niche with engineering innovation, our work aims to provide a cohesive framework and forward-looking perspective to guide the development of effective, microenvironment-targeted regenerative strategies. Scheme 1: Schematic overview of the osteoporotic bone microenvironment and therapeutic strategies using engineered biomaterials. The figure emphasizes the central role of cellular dysfunction in osteoporosis, characterized by an imbalance between enhanced osteoclastic activity and diminished osteoblastic function. This dysfunction occurs within, and is aggravated by, a chronic inflammatory immune microenvironment featuring increased pro-inflammatory cytokine levels, decreased anti-inflammatory cytokine levels, and abnormal immune cell activation, which further disrupts bone homeostasis. To reverse this pathological milieu, a diverse array of biomaterials is illustrated, such as ion-releasing, metabolite-based, ECM-mimetic, and cytokine-loaded biomaterials. This figure was created in BioRender.com . • The review elucidates how cellular, signaling, and immune imbalances drive osteoporotic bone microenvironment pathology. • A component-centric taxonomy categorizes biomaterials into ion, metabolite, ECM-mimetic, and cytokine systems. • Material design strategies for reprogramming the pathological niche to enhance bone regeneration are evaluated. • Translational hurdles and the role of bone organoids and AI in accelerating therapeutic development are discussed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Bone Metabolism and Diseases · Bone health and osteoporosis research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Osteoporosis treatment: current drugs and future developments
2. Correlations between sagittal parameters and functional scores in 65-Year-Old osteoporotic females with vertebral body fracture under low-energy mechanism10.3390/jcm13030774 ↗
3. Rates of osteoporosis screening and treatment following vertebral fracture10.1016/j.spinee.2018.08.004 ↗
4. Multivitamins and risk of fragility hip fracture: a systematic review and meta-analysis10.1007/s11657-021-00893-x ↗
5. Therapeutic potential of Stearoyl-CoA Desaturase1 (SCD1) in modulating the effects of fatty acids on osteoporosis10.3390/cells13211781 ↗
6. An overview and management of osteoporosis10.5152/eurjrheum.2016.048 ↗
7. Effect of osteoporosis treatment on mortality: a meta-analysis10.1210/jc.2009-0852 ↗
8. Major osteoporotic fragility fractures: Risk factor updates and societal impact10.5312/wjo.v7.i3.171 ↗
9. Projection of osteoporosis-related fractures and costs in China: 2010-205010.1007/s00198-015-3093-2 ↗
10. Single-cell transcriptomic analysis reveals AP-1 downregulation remodels bone marrow environment and contributes to osteopenia in ovariectomized mice
11. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis10.1016/j.bone.2008.02.017 ↗
12. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover10.3390/ijms23031376 ↗
13. Loss of Rictor with aging in osteoblasts promotes age-related bone loss10.1038/cddis.2016.249 ↗
14. Consequences of aging on bone
15. Drug therapy for osteoporosis in older adults10.1016/S0140-6736(21)02646-5 ↗
16. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis10.1007/s00198-013-2576-2 ↗
17. Bisphosphonates for the treatment of osteoporosis: insights for clinicians10.1177/2040622310374783 ↗
18. Primary osteoporosis induced by androgen and estrogen deficiency: the molecular and cellular perspective on pathophysiological mechanisms and treatments10.3390/ijms252212139 ↗
19. Puerarin improves the bone micro-environment to inhibit OVX-Induced osteoporosis via modulating SCFAs released by the gut microbiota and repairing intestinal mucosal integrity10.1016/j.biopha.2020.110923 ↗
20. Microenvironment-targeted strategy steers advanced bone regeneration
21. Regulation of extracellular bioactive cations in bone tissue microenvironment induces favorable osteoimmune conditions to accelerate in situ bone regeneration
22. MOF-based guided bone regeneration membrane for promoting osteogenesis by regulating bone microenvironment through Cascade effects
23. ROS/MMP-9 mediated CS degradation in BMSC inhibits citric acid metabolism participating in the dual regulation of bone remodelling10.1038/s41420-024-01835-5 ↗
24. The diamond concept enigma: recent trends of its implementation in cross-linked chitosan-based scaffolds for bone tissue engineering10.1021/acsabm.3c00108 ↗
25. Regulation of bone by mechanical loading, sex hormones, and nerves: integration of such regulatory complexity and implications for bone loss during space flight and post-menopausal osteoporosis10.3390/biom13071136 ↗
26. Osteoporotic osseointegration: therapeutic hallmarks and engineering strategies10.7150/thno.96516 ↗
27. Bioactive materials-mediated regulation of bone marrow microenvironment: mechanistic insights and therapeutic potentials
28. Frizzled receptors: gatekeepers of wnt signaling in development and disease10.3389/fcell.2025.1599355 ↗
29. The regulation of bone metabolism and disorders by wnt signaling10.3390/ijms20225525 ↗
30. Anti-osteoporosis effects and underpinning mechanisms of food-derived bioactive peptides: a review10.1016/j.tifs.2024.104431 ↗
31. Insulin growth factor-1 promotes the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells through the Wnt/β-catenin pathway10.3892/etm.2021.10323 ↗
32. From bone marrow mesenchymal stem cells to diseases: the crucial role of m(6)A methylation in orthopedics10.1186/s13287-025-04364-9 ↗
33. Aluminum trichloride inhibited osteoblastic proliferation and downregulated the Wnt/β-Catenin pathway10.1007/s12011-016-0880-3 ↗
34. Application of BMP in bone tissue engineering
35. BMP-2-induced osterix expression is mediated by Dlx5 but is independent of Runx210.1016/j.bbrc.2003.08.058 ↗
36. Engineered BMP2/BMP7 extracellular vesicles induce autocrine BMP release driving SMAD phosphorylation to promote bone formation10.1038/s41536-025-00405-2 ↗
37. Notch signaling pathway in osteogenesis, bone development, metabolism, and diseases10.1096/fj.202402545R ↗
38. Hedgehog signaling controls bone homeostasis by regulating osteogenic/adipogenic fate of skeletal stem/progenitor cells in mice10.1002/jbmr.4485 ↗
39. The IFT80/Hedgehog pathway regulates the osteogenic-adipogenic differentiation of bone marrow mesenchymal stem cells
40. Notch signaling pathway promotes osteogenic differentiation of mesenchymal stem cells by enhancing BMP9/Smad signaling10.3892/ijmm.2017.3037 ↗
41. Bioactive manganese-decorated titanium implants for osteoporotic bone regeneration10.1016/j.mtadv.2024.100542 ↗
42. Calcium phosphate bone cements with α-ketoglutarate polyester microspheres promote osteoporotic bone defect repair10.1039/D5TB00380F ↗
43. KLF2 regulates osteoblast differentiation by targeting of Runx210.1038/s41374-018-0149-x ↗
44. Regulation of proliferation, differentiation and functions of osteoblasts by Runx210.3390/ijms20071694 ↗
45. BMP2 regulates osterix through Msx2 and Runx2 during osteoblast differentiation10.1074/jbc.M801774200 ↗
46. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders10.1016/S0002-9440(10)63208-7 ↗
47. Ultrastructure and biological function of matrix vesicles in bone mineralization10.1007/s00418-018-1646-0 ↗
48. Alkaline phosphatase: structure, expression and its function in bone mineralization10.1016/j.gene.2020.144855 ↗
49. Effects of HA released calcium ion on osteoblast differentiation10.1007/s10856-010-4011-y ↗
50. Role of phosphate in biomineralization10.1007/s00223-020-00729-9 ↗
51. RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor10.1016/j.str.2012.08.030 ↗
52. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density10.1016/S0092-8674(00)80209-3 ↗
53. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL10.1073/pnas.95.7.3597 ↗
54. Osteoblast-osteoclast communication and bone homeostasis10.3390/cells9092073 ↗
55. Macrophage colony-stimulating factor release and receptor expression in bone cells10.1002/jbmr.5650081214 ↗
56. Piezoelectric signals in vascularized bone regeneration
57. Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells10.1210/endo.136.11.7588206 ↗
58. Endocrine role of bone in the regulation of energy metabolism10.1038/s41413-021-00142-4 ↗
59. Bone augmentation with autologous tooth shell in the esthetic zone for dental implant restoration: a pilot study10.1186/s40729-021-00389-w ↗
60. T cell protein tyrosine phosphatase in osteoimmunology
61. TNF-α and IL-6: the link between immune and bone system
62. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors10.1084/jem.190.12.1741 ↗
63. Icariin attenuates thioacetamide-induced bone loss via the RANKL-p38/ERK-NFAT signaling pathway10.3892/mmr.2022.12642 ↗
64. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways10.1016/j.biopha.2022.112902 ↗
65. Protein phosphatase 1 regulatory subunit 18 suppresses the transcriptional activity of NFATc1 via regulation of c-fos
66. AP-1 and mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors10.1002/jcb.28504 ↗
67. Inhibitory effect of a rosmarinic acid-enriched fraction prepared from nga-mon (Perilla frutescens) seed meal on osteoclastogenesis through the RANK signaling pathway10.3390/antiox10020307 ↗
68. Primary biliary cirrhosis and osteoporosis: a bidirectional two-sample Mendelian randomization study10.3389/fimmu.2023.1269069 ↗
69. Targeting STING: from antiviral immunity to treat osteoporosis
70. The sealing zone in osteoclasts: a self-organized structure on the bone10.3390/ijms19040984 ↗
71. Osteoclast and osteoblast responsive carbonate apatite coatings for biodegradable magnesium alloys10.1080/14686996.2020.1761237 ↗
72. The extracellular matrix and the immune system: a mutually dependent relationship10.1126/science.abp8964 ↗
73. Biomimetic Scaffolds-A novel approach to three dimensional cell culture techniques for potential implementation in tissue engineering10.3390/nano14060531 ↗
74. Force triggers YAP nuclear entry by regulating transport across nuclear pores10.1016/j.cell.2017.10.008 ↗
75. Designing stem cell niches for differentiation and self-renewal10.1098/rsif.2018.0388 ↗
76. Hippo-YAP/TAZ signaling in osteogenesis and macrophage polarization: therapeutic implications in bone defect repair10.1016/j.gendis.2022.12.012 ↗
77. Click chemistry plays a dual role in biodegradable polymer design10.1002/adma.201305162 ↗
78. The effect on osteoblast function of colocalized RGD and PHSRN epitopes on PEG surfaces10.1016/j.biomaterials.2005.01.045 ↗
79. Research progress on osteoclast regulation by biodegradable magnesium and its mechanism10.1093/rb/rbaf026 ↗
80. NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis10.1371/journal.pone.0015383 ↗
81. Learning from BMPs and their biophysical extracellular matrix microenvironment for biomaterial design10.1016/j.bone.2020.115540 ↗
82. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation10.1371/journal.pone.0036786 ↗
83. Genetics and epigenetics of bone remodeling and metabolic bone diseases10.3390/ijms23031500 ↗
84. Citrate: a key signalling molecule and therapeutic target for bone remodeling disorder
85. Essential role of the metabolite α-ketoglutarate in bone tissue and bone-related diseases10.3724/abbs.2025020 ↗
86. Citrate-based materials fuel human stem cells by metabonegenic regulation10.1073/pnas.1813000115 ↗
87. Wang · 2023 · 6 · 152
88. Synthesis and characterization of anti-bacterial and anti-fungal citrate-based mussel-inspired bioadhesives10.1016/j.biomaterials.2016.01.069 ↗
89. Injectable citrate-based polyurethane-urea as a tug-of-war-inspired bioactive self-expansive and planar-fixing screw augmented bone-tendon healing
90. The status of citrate in the hydroxyapatite/collagen complex of bone; and its role in bone formation10.7243/2050-1218-3-4 ↗
91. Citrate stabilizes hydroxylapatite precursors: implications for bone mineralization10.1021/acsbiomaterials.1c00196 ↗
92. Strongly bound citrate stabilizes the apatite nanocrystals in bone10.1073/pnas.1009219107 ↗
93. Citrate improves collagen mineralization via interface wetting: a physicochemical understanding of biomineralization control10.1002/adma.201704876 ↗
94. Tricarboxylic acid cycle regulation of metabolic program, redox system, and epigenetic remodeling for bone health and disease10.3390/antiox13040470 ↗
95. Anti-inflammatory effects of calcium citrate in RAW 264.7cells via suppression of NF-κB activation10.1016/j.etap.2014.11.002 ↗
96. 3D printed composite scaffold accelerates bone regeneration by modulating immunity and promoting angiogenesis10.1016/j.jmst.2025.03.041 ↗
97. Synthesis and characterization of biomimetic citrate-based biodegradable composites10.1002/jbm.a.34928 ↗
98. Citrate-based biodegradable injectable hydrogel composites for orthopedic applications10.1039/C2BM00026A ↗
99. Citrate-based biphasic scaffolds for the repair of large segmental bone defects10.1002/jbm.a.35228 ↗
100. Development of injectable citrate-based bioadhesive bone implants10.1039/C4TB01498G ↗